biotech / news / / Reuters
The companies tested Merck's Keytruda and Eisai's Lenvima as a first-line treatment for patients with clear cell renal cell carcinoma.
Merck and Eisai's new drug combinations did not outperform Keytruda-Lenvima for kidney cancer.
KEY POINTS
- Neither the Welireg nor the MK-1308A combinations met the study's two main efficacy goals.
- The trial setback derails a near-term approval path for Welireg in first-line kidney cancer.
- The safety profiles of the tested combinations matched previous studies without new safety concerns.
- Analysts now question Welireg's previously projected peak sales potential beyond $2 billion.
COMPANIES
Summarized by Newsio from Reuters. How we summarize →